Fineotex Chemical Limited reported strong consolidated revenue growth in Q1, with revenue from operations rising to 3.77B Rupees from 1.37B Rupees in the same period last year, reflecting a substantial year-on-year expansion. Consolidated net profit for the quarter came in at 384M Rupees compared to 248M Rupees in the corresponding period of the previous year. EBITDA stood at 591M Rupees versus 252M Rupees year-on-year, though the EBITDA margin contracted to 15.70% from 18.38% in the prior-year period, indicating that operating costs scaled at a faster pace than revenue during the quarter. The strong financial performance was further supported by a 130.84% increase in volume, indicating robust demand across its speciality chemicals segment.

The Board of Directors approved the unaudited standalone and consolidated financial results on July 23, 2026, following a meeting that commenced at 3.50 P.M. and concluded at 5.00 P.M. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, ASL & Co. Chartered Accountants, who issued an unqualified report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial statements were prepared in accordance with Ind AS 34, "Interim Financial Reporting," prescribed under Section 133 of the Companies Act, 2013.

Consolidated Financial Performance

The consolidated revenue from operations stood at ₹37,662.77 Lakhs for the quarter ended June 30, 2026, a substantial increase from ₹13,707.20 Lakhs in Q1FY26. Other income contributed ₹1,008.89 Lakhs, bringing total income to ₹38,671.66 Lakhs. Total expenses were recorded at ₹32,197.39 Lakhs, including cost of materials consumed at ₹24,831.46 Lakhs and employee benefit expenses at ₹2,683.20 Lakhs. Finance costs remained minimal at ₹10.10 Lakhs. The profit before tax was ₹6,474.27 Lakhs, against which tax expenses of ₹1,653.74 Lakhs (current tax of ₹1,689.98 Lakhs less deferred tax benefit of ₹36.24 Lakhs) were charged.

The key consolidated financial metrics for the quarter are summarised below:

Standalone Results and Subsidiary Impact

On a standalone basis, Fineotex Chemical reported revenue from operations of ₹8,514.55 Lakhs, a decrease from ₹9,825.59 Lakhs in the corresponding quarter of the previous year. Standalone PAT was ₹2,052.60 Lakhs, slightly higher than the ₹1,989.38 Lakhs reported in Q1FY26. The divergence between consolidated and standalone performance highlights the significant contribution from subsidiaries. The consolidated results include thirteen subsidiaries whose interim financial information was unaudited and unreviewed, contributing total revenue of ₹31,082.51 Lakhs and PAT of ₹2,767.94 Lakhs for the quarter. Key subsidiaries include Manya Manufacturing India Private Limited, Fineotex Biotex Healthguard FZE, and Fineotex Malaysia Limited.

What the Numbers Show

The data reveals a distinct shift in value creation towards the group's international and subsidiary operations. While the parent entity's revenue declined modestly, the consolidated revenue more than doubled, driven by the subsidiary network which accounted for approximately 80% of the total consolidated revenue. The EBITDA margin compression to 15.70% from 18.38% year-on-year suggests that operating costs scaled at a faster pace relative to revenue during the period of rapid volume expansion. Additionally, the company maintained a healthy ROIC of approximately 33.06%, indicating effective utilization of invested capital despite the rapid scale-up in volumes.

Legal Dispute and Dividend Update

A legal dispute concerning the Assignment Agreement for a property classified as 'Assets Held for Sale' remains unsettled as of June 30, 2026. The company has paid ₹625.00 Lakhs towards the settlement and received a total advance of ₹1,008.00 Lakhs from a third party under a Memorandum of Understanding entered into in Q4FY26. However, as the transfer was not completed by the quarter-end, the sale has not been recognized in the financials. Furthermore, the Board had previously recommended a final dividend of ₹0.05 per equity share for FY26, subject to shareholder approval.

Fineotex Chemical Limited has scheduled an investor and analyst conference call to discuss the operational and financial performance for Q1 FY27. The meeting will take place on July 24, 2026, at 5:00 PM IST. This session allows stakeholders to review the company's quarterly results directly with its management team.

The disclosure was made pursuant to Regulation 30(6) read with Para A Part A of Schedule III of the SEBI (LODR) Regulations 2015. The company has provided access details for participants to join the discussion remotely.

Conference Call Details

The conference will be held over the phone, with specific access numbers provided for domestic and international participants. The schedule for the earnings call is outlined below:

Access Numbers

Participants can dial in using the following primary and toll-free numbers:

Key Participants

The discussion will be led by the company's senior leadership, including:

• Ms. Aarti Jhunjhunwala – Executive Director
• Mr. Yusuf K Contractor – Head - M&A and Investor Relations
• Mr. Arindam Choudhuri – Chief Executive Officer (Textile)
• Mr. Sanjay Tibrewala – Executive Director

RSVP details for the event have been managed by Adfactors PR.